



SDI Review Form 1.6

Journal Name:	<u>British Journal of Medicine and Medical Research</u>
Manuscript Number:	Ms_BJMMR_19334
Title of the Manuscript:	Comparison of Buprenorphine and Bupropion in the treatment of Methamphetamine dependency and Craving
Type of the Article	Case Study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Compulsory REVISION comments	<p>The study focuses on a single clinic case from which it is not possible to deduce general feedback on the effectiveness of the two drugs used for the treatment of the methamphetamine craving.</p> <p>It would be appropriate to include a bibliographic reference to define what type of craving score was used. Considering that the patient abused heroin and methamphetamine for five years, it seems normal that the treatment with Buprenorphine, a very effective drug in the treatment of opioid dependence, has positively influenced the remission during the initial hospitalization.</p> <p>Therefore it must be defined for how many weeks it is prolonged the remission before the resumption of only methamphetamine.</p> <p>During the second admission it was given bupropion sustained-release?</p> <p>After the second discharge which type of therapy has been prescribed?</p> <p>The discussion is really insufficient. Before the conclusions would be appropriate an in-depth discussion taking into account other studies on the treatment of methamphetamine craving.</p>	



SDI Review Form 1.6

	<p>Ethical issue: Statements about the patient's informed consent and the approval by the ethics committee are not included</p>	
--	---	--



SDI Review Form 1.6

Minor REVISION comments		
Optional/General comments	<p>The following publications may be of interest to the discussion:</p> <p>1) Anderson AL, Li SH, Markova D et al. <i>Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial</i>. Drug Alcohol Depend. 2015 May 1;150:170-4. doi: 10.1016/j.drugalcdep.2015.01.036. Epub 2015 Feb 7.</p> <p>2) Laurent Karila, Aviv Weinstein, Henri-Jean Aubin, et al., <i>Pharmacological approaches to methamphetamine dependence: a focused review</i> , Br J Clin Pharmacol. 2010 Jun; 69(6): 578–592.</p> <p>3) Elkashef A, Vocci F, Hanson G, et al. , <i>Pharmacotherapy of methamphetamine addiction: an update</i>. Subst Abus. 2008;29(3):31-49. doi: 10.1080/08897070802218554.</p>	

Reviewer Details:

Name:	Renata Borriello
Department, University & Country	Dep. of Experimental Medicine, University of Naples, Italy